NCL Method ITA-1
Analysis of Hemolytic Properties of Nanoparticles
Listed in Datasets | publication by group NCL Protocols
Version 2.0 - published on 09 Jul 2020 doi:10.17917/XJ16-D110 - cite this Last public release: 2.0b
Licensed under these terms
Description
Erythrocytes comprise approximately 45% of whole blood by volume. Hemolysis refers to the damage of red blood cells leading to the release of erythrocyte intracellular content into blood plasma. When it occurs, in vivo hemolysis can lead to anemia, jaundice and other pathological conditions, which may become life threatening. Hemoglobin is a dominant protein carried by erythrocytes. When it is contained inside the cell it plays a key role in carrying oxygen to other cells and tissues. However, extracellular hemoglobin is toxic and may affect vascular, myocardial, renal and central nervous system functions. Therefore, all medical devices and drugs which come in contact with blood are required to be tested for potential hemolytic properties.
Content List
- NCL_Method_ITA-1_May2020.pdf(PDF | 668 KB)
Cite this work
Researchers should cite this work as follows:
- Barry Neun, Edward Cedrone, Marina Dobrovolskaia (2020). NCL Method ITA-1. (Version 2.0). NCI Hub. doi:10.17917/XJ16-D110
Tags
NCL Protocols
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.